Trevi Therapeutics Inc. – Material Contracts Watch

from 10-K 4 pages November 24, 2025 • Base Salary: Your Base Salary Will Be at the Rate of $20,076.92 Per Bi-Weekly Pay Period (Which if Annualized Equals $522,000), Payable in Accordance With the Regular Payroll Practices of the Company and Subject to All Applicable Deductions and Withholdings

from 10-K 2 pages Non-Employee Director Compensation Program

from 10-Q 7 pages August 14, 2025 • as of the Separation Date, All Salary Payments From the Company Will Cease and Any Benefits You Had as of the Separation Date Under Company-Provided Benefit Plans, Programs, or Practices Will Terminate, Except as Required by Federal or State Law. • You Will Receive the Accrued Obligations Described in Section 6(a) of the Company’s Executive Separation Benefits and Retention Plan (The “Separation Benefits Plan”) in Accordance With the Terms and Conditions of the Separation Benefits Plan. • You May, if Eligible and at Your Own Cost, Elect to Continue Receiving Group Medical Insurance Pursuant to the “Cobra” Law. Please Consult the Cobra Materials to Be Provided Under Separate Cover for Details Regarding These Benefits

from 10-K 2 pages Non-Employee Director Compensation Program

from 10-Q 4 pages September 27, 2024

from 10-Q 14 pages Consulting Services Agreement

from 10-K 17 pages Second Amendment to Lease

from 10-K 4 pages Material contract

from 10-Q 9 pages Consulting Services Agreement

from 8-K 11 pages Amendment No. 1 to Sales Agreement

from 10-Q 3 pages Material contract

from 10-Q 4 pages Material contract

from 10-Q 2 pages First Amendment to Exclusive License Agreement This First Amendment to Exclusive License Agreement (Hereinafter the "First

from 10-K 1 page Non-Employee Director Compensation Program

from 10-K 14 pages Trevi Therapeutics, Inc. Employment Agreement

from 8-K 14 pages Trevi Therapeutics, Inc. Executive Separation Benefits and Retention Plan

from S-1/A 18 pages Share Purchase Agreement

from S-1/A 38 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Exclusive License Agreement by and Between Trevi Therapeutics, Inc. and Penwest Pharmaceuticals Co

from S-1 28 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Exclusive License Agreement Between Rutgers, the State University of New Jersey and Trevi Therapeutics, Inc. Effective November 6, 2018

from S-1 38 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Exclusive License Agreement by and Between Trevi Therapeutics, Inc. and Penwest Pharmaceuticals Co